CFHR5
protein-codingcomplement factor H related 5, the group of Sushi domain containing|Complement system regulators and receptors
Gene summary
This gene is a member of a small complement factor H (CFH) gene cluster on chromosome 1. Each member of this gene family contains multiple short consensus repeats (SCRs) typical of regulators of complement activation. The protein encoded by this gene has nine SCRs with the first two repeats having heparin binding properties, a region within repeats 5-7 having heparin binding and C reactive protein binding properties, and the C-terminal repeats being similar to a complement component 3 b (C3b) binding domain. This protein co-localizes with C3, binds C3b in a dose-dependent manner, and is recruited to tissues damaged by C-reactive protein. Allelic variations in this gene have been associated, but not causally linked, with two different forms of kidney disease: membranoproliferative glomerulonephritis type II (MPGNII) and hemolytic uraemic syndrome (HUS). [provided by RefSeq, Jan 2010]
- CFHL5
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~34.7 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0013892
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0013892
Submitter: Ambry Genetics
Clinical Genomic Database (CGD)
Manifestation: Renal
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to CFHR5 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_030787.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 7 | 37 | 1 | 45 | ||
| missense | 174 | 49 | 1 | 224 | ||
| nonsense | 2 | 15 | 1 | 18 | ||
| start loss | 1 | 1 | ||||
| frameshift | 2 | 19 | 21 | |||
| splice donor/acceptor (+/-2bp) | 4 | 1 | 5 | |||
| Total | 0 | 4 | 220 | 88 | 2 | 314 |
Highest pathogenic variant AF is 0.0000310016
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_110414.1 | 10 | MANE Select | |
| Ensembl | ENSP00000256785.4 | 10 | MANE Select | |
| Ensembl | ENSP00000514393.1 | 8 | Standard | |
| Ensembl | ENSP00000514393.1 | 8 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Innate Immune System
- Immune System
- Regulation of Complement cascade
- Complement cascade
Biological Process
- complement activation, alternative pathway
- regulation of complement activation
- negative regulation of protein binding
- positive regulation of cytolysis
Molecular Function
- protein binding
- protein homodimerization activity
- protein heterodimerization activity
Cellular Component
- extracellular region
- protein-containing complex
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000256785
- Coding exons
- 10
- Length
- 32138
- Individuals with no LoFs
- 125379
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 364
- Defined
- 125743
- p
- 0.00145
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.903 | 349 | 305 | 1.15 | 0.0000150 | 3702 |
| Missense (PolyPhen) | 115 | 108.61 | 1.0589 | 1281 | ||
| Synonymous | -1.91 | 130 | 105 | 1.24 | 0.00000542 | 1046 |
| Loss of Function | -2.16 | 41 | 28.5 | 1.44 | 0.00000140 | 361 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00074 | 0.00074 | rare |
| Latino/Admixed American | 0.00075 | 0.00075 | rare |
| Ashkenazi Jewish | 0.000099 | 0.000099 | rare |
| East Asian | 0.00033 | 0.00033 | rare |
| Finnish | 0.00018 | 0.00018 | rare |
| European (Non-Finnish) | 0.00011 | 0.00011 | rare |
| South Asian | 0.0095 | 0.0095 | notable |
| Other | 0.0021 | 0.0021 | notable |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the physiological complement inhibitor CFH. {ECO:0000269|PubMed:23487775}.;
- Disease
- DISEASE: CFHR5 deficiency (CFHR5D) [MIM:614809]: A progressive disease characterized by glomerulonephritis, hematuria, renal failure, end-stage renal disease, subendothelial and mesangial glomerular C3 deposits, mesangial matrix expansion, increased glomerular cellularity, and segmental capillary wall thickening. Hematuria may become apparent after respiratory infections. {ECO:0000269|PubMed:20800271, ECO:0000269|PubMed:22503529}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Intolerance Scores
- LoFtool
- 0.613
- RVIS EVS
- 0.18
- RVIS percentile EVS
- 66.24
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.588
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |